Literature DB >> 12884230

Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.

Konstantinos M Stamou1, Stavros Karakozis, Paul H Sugarbaker.   

Abstract

BACKGROUND AND OBJECTIVES: The optimal management of symptomatic advanced peritoneal carcinomatosis of non-gynecologic origin is not defined. Historic controls of surgical efforts report high postoperative mortality and morbidity rates with equivocal palliation. Novel surgical procedures need to be tested in terms of the impact on survival and quality of life. STUDY
DESIGN: We studied 46 consecutive patients who underwent total abdominal colectomy, pelvic peritonectomy with construction of an end-ileostomy for palliation of peritoneal carcinomatosis.
RESULTS: Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy was successfully performed in 46 patients of median age of 54.4 years. Overall median survival was 10.7 months, with a mean follow-up period of 12 months. Patients with appendiceal malignancy had a median survival of 19.7 months. Prognosis was poorer for patients with colon cancer, who had a median survival of 7.0 months, while patients with primary peritoneal carcinomatosis had a median of 7.8 months. Postoperative morbidity and mortality rates were 19.5 and 8.6%, respectively.
CONCLUSIONS: Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy is a technically feasible procedure and is advocated for the palliation of patients with peritoneal carcinomatosis of appendiceal origin. It is not clear if the procedure should be advocated for more invasive gastrointestinal malignancies. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884230     DOI: 10.1002/jso.10270

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer.

Authors:  Antonios-Apostolos K Tentes; Stylianos Kakolyris; Dimitrios Kyziridis; Christina Karamveri
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

Review 2.  Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?

Authors:  John Spiliotis
Journal:  Ann Transl Med       Date:  2020-12

Review 3.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

Authors:  McKayla J Riggs; Prakash K Pandalai; Joseph Kim; Charles S Dietrich
Journal:  Diagnostics (Basel)       Date:  2020-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.